A case of unknown primary melanoma detected with a BRAF gene mutation from a pleural fluid cell block
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16812 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Sotaro Yamamoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Neoplasms, Unknown Primary, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
The treatment course of patients with advanced melanoma carrying a BRAF V600 mutation has significantly changed since the use of BRAF/MEK inhibitors, as evidenced by clinically significant responses.1 Moreover, the overall response rate to the combination therapy of dabrafenib and trametinib has been reported to be 83%.2 Although it is important to identify BRAF mutations in melanomas, occasionally sufficient specimens cannot be obtained and BRAF mutation analysis cannot be performed. Here, we report a case of a patient with an unknown primary melanoma carrying BRAF mutation, detected using a pleural fluid cell block. A 54-year-old woman presented with respiratory distress at our hospital. Chest computed tomography (CT) showed right pleural effusion and mediastinal lymph node metastases (Figure 1a). Pleural fluid cytology revealed the presence of tumor cells with brown cytoplasmic granules. The diagnosis of melanoma was confirmed by immunohistochemical staining, which tested positive for HMB-45 and Melan-A (Figure 1b–e). Positron emission tomography revealed no abnormalities other than pleural effusion, mediastinal lymph node metastasis, and pleural dissemination. Based on these findings, the patient was diagnosed with a melanoma of unknown primary origin. It was difficult to obtain a biopsy of the pleural dissemination because of decreased oxygenation and worsening performance status (PS3 on the Eastern Cooperative Oncology Group [ECOG] scale). BRAF mutation analysis (Cobas 4800 BRAF V600 Mutation Test; Roche Molecular Diagnostics) was performed using pleural effusion cell blocks. Cell blocks were prepared by the plasma thrombin method. The plasma of the patient and reagents (coagpia PT-Liquid®; Sekisui Medical Co.) were added to the effusion sediment and centrifuged, and the clotted specimens were formalin-fixed and paraffin-embedded to block cells. Because the analysis revealed BRAF mutation (V600E), treatment with BRAF/MEK inhibitors was initiated, which reduced the pleural fluid, number of metastatic lymph nodes, and pleural dissemination (Figure 1f). The patient has been alive to date, has been partially responding to treatment for 6 months, and her PS is 0. The initial serum lactate dehydrogenase (LDH) level was 477 U/L, and 1 month later it decreased to 305 U/L. It has been within normal limits to date. Immunostaining and gene mutation analysis can be performed using pleural fluid cell blocks in cases of lung cancer and breast cancer.3 For example, a study using pleural fluid cell blocks reported no significant difference in EGFR gene mutations in non-small-cell lung cancer between tissue samples and pleural fluid cell blocks.4 In melanoma, it is usually not difficult to obtain tissue samples from the primary tumor. However, it is preferred to conduct mutation analysis with metastatic specimens due to the 13% discrepancy between the primary tumor and metastases.5 Especially in cases where the only available sample was a pleural effusion, as in this case, pleural fluid cell block specimens are a useful option to check for BRAF mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Dermatology, Kumamoto Red Cross Hospital, Kumamoto, Japan.
ORCID-Profile: Sotaro Yamamoto, Haruka Kuriyama, Kayo Kashiwada-Nakamura, Ikko Kajihara, Jun Aoi
Zitieren
APA
Yamamoto, S., Kuriyama, H., Kashiwada-Nakamura, K., Kajihara, I., Makino, K., Aoi, J., Miyashita, A., Yoshida, C., Kubo, Y., & Fukushima, S. (2023). A case of unknown primary melanoma detected with a BRAF gene mutation from a pleural fluid cell block. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16812
Vancouver
Yamamoto S, Kuriyama H, Kashiwada-Nakamura K, Kajihara I, Makino K, Aoi J, et al. A case of unknown primary melanoma detected with a BRAF gene mutation from a pleural fluid cell block. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16812
BibTeX
@article{Yamamoto2023,
author = {Yamamoto, Sotaro and Kuriyama, Haruka and Kashiwada-Nakamura, Kayo and Kajihara, Ikko and Makino, Katsunari and Aoi, Jun and Miyashita, Azusa and Yoshida, Chieko and Kubo, Yosuke and Fukushima, Satoshi},
title = {A case of unknown primary melanoma detected with a BRAF gene mutation from a pleural fluid cell block},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16812}
}
EUVIMED